Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Verastem Inc. is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 4 distinct examiners and 4 distinct art units, reflecting a range of pharmaceutical research currently under review. This distribution indicates that the company's innovations span several technical classifications at the USPTO. Engaging with 4 distinct art units allows the company to protect its innovations across multiple specialized sections.
The busiest examiner for the portfolio is JAVANMARD, SAHAR, who is responsible for 2 pending office actions. While the company deals with 4 distinct examiners, this individual manages a larger portion of the 5 pending office actions. Practitioners should note that the decisions of this examiner will have a significant impact on the portfolio's immediate success. Managing the 2 pending office actions under this examiner requires a focused strategy to ensure consistency across the company's pharmaceutical applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAVANMARD, SAHAR | 2 | 64.9% | +34.1% |
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
| HIRAKIS, SOPHIA P | 1 | 57.4% | +69.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | JAVANMARD, SAHAR | 142d overdue |
| 18704267 | METHODS OF TREATING ABNORMAL CELL GROWTH | ARCORIA, PAUL JOSEPH | — |
| 18263820 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | SEITZ, ANTHONY JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | JAVANMARD, SAHAR | 142d overdue |
| 18263820 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | SEITZ, ANTHONY JOSEPH | — |
| 17989006 | METHODS AND COMPOSITIONS FOR TREATING ABNORMAL CELL GROWTH | JAVANMARD, SAHAR | — |
| 17921509 | METHODS OF TREATING ABNORMAL CELL GROWTH | HIRAKIS, SOPHIA P | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1621 | 1 |
| 1629 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704267 | METHODS OF TREATING ABNORMAL CELL GROWTH | ARCORIA, PAUL JOSEPH | 1621 | §103§112 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18263820 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | SEITZ, ANTHONY JOSEPH | 1629 | §102§103 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | JAVANMARD, SAHAR | 1622 | §103§112Other | Final Rejection | 142d overdue | Pending | Dec 21, 2022 |
| 17989006 | METHODS AND COMPOSITIONS FOR TREATING ABNORMAL CELL GROWTH | JAVANMARD, SAHAR | 1622 | §103§112DP | Final Rejection | — | Pending | Nov 17, 2022 |
| 17921509 | METHODS OF TREATING ABNORMAL CELL GROWTH | HIRAKIS, SOPHIA P | 1623 | §103 | Non-Final OA | — | Pending | Oct 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVerastem Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Sahar Javanmard has the most, with 2 of Verastem Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
